Plague vaccines: Current developments and future perspectives

Emerging Microbes and Infections

Volumn 1, Issue , 2012, Pages

  Feodorova, Valentina A ^a   Motin, Vladimir L ^b  

^a Federal Agency of Scientific Organizations   (Russian Federation)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Plague; Protective antigens; Vaccine; Yersinia pestis

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL VECTOR; CAPSULAR SUBUNIT PROTEIN F1; CHOLERA TOXIN; DNA; DNA VACCINE; LOW CALCIUM RESPONSE V ANTIGEN; PLAGUE VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANTIGEN EXPRESSION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM CULTURE; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SAFETY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; KILLED WHOLE CELL; LIVE WHOLE CELL; LIVER; MICROBIAL ATTENUATION; NONHUMAN; PLAGUE; PLANT; PRIMATE; PRIORITY JOURNAL; REVIEW; WHOLE CELL; YERSINIA PESTIS;

ANIMALIA; BACTERIA (MICROORGANISMS); YERSINIA PESTIS;

EID: 84878369905     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2012.34     Document Type: Review

References (72)

1. Perry RD, Fetherston JD. Yersinia pestis - etiologic agent of plague. Clin Microbiol Rev 1997; 10: 35-66. (Pubitemid 27042831)
2. Gage KL, Kosoy MY. Natural history of plague: perspectives from more than a century of research. Annu Rev Entomol 2005; 50: 505-528.
3. Inglesby TV, Dennis DT, Henderson DA et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 2000; 283: 2281-2290. (Pubitemid 30246781)
4. Feodorova VA, Corbel MJ. Prospects for new plague vaccines. Expert Rev Vaccines 2009; 8: 1721-1738.
5. Galimand M, Guiyoule A, Gerbaud G et al. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Eng J Med 1997; 337: 677-680. (Pubitemid 27375474)
6. Guiyoule A, Gerbaud G, Buchrieser C et al. Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis. Emerg Infect Dis 2001; 7: 43-48. (Pubitemid 32173332)
7. Kiefer D, Dalantai G, Damdindorj T et al. Phenotypical characterization of Mongolian Yersinia pestis strains. Vector Borne Zoonotic Dis 2012; 12: 183-188.
8. Bos KI, Schuenemann VJ, Golding GB et al. A draft genome of Yersinia pestis from victims of the Black Death. Nature 2011; 478: 506-510.
9. Morelli G, Song Y, Mazzoni CJ et al. Yersinia pestis genome sequencing identifies patterns of global phylogenetic diversity. Nat Genet 2010; 42: 1140-1143.
10. Girard G. [Immunity in plague infection. Results of 30 years of work with the Pasteurella pestis EV strain (Girard and Robic).] Biol Med (Paris) 1963; 52: 631-731. French.
11. Russell P, Eley SM, Hibbs SE, Manchee RJ, Stagg AJ, Titball RW. A comparison of plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestisin a murine model. Vaccine 1995; 13: 1551-1556.
12. Meyer KF. Effectiveness of live or killed plague vaccines in man. Bull WHO 1970; 42: 653-666.
13. Meyer KF, Smith G, Foster L, Brookman M, Sung M. Live, attenuated Yersinia pestis vaccine: virulent in nonhuman primates, harmless to guinea pigs. J Infect Dis 1974; 129(Suppl): S85-S112.
14. Korobkova EI. Live antiplague vaccine. Moscow: Medgiz, 1956.
15. Fetherston JD, Schuetze P, Perry RD. Loss of the pigmentation phenotype in Yersinia pestis is due to the spontaneous deletion of 102 kb of chromosomal DNA which is flanked by a repetitive element. Mol Microbiol 1992; 6: 2693-2704.
16. 1 is flanked by an insertion sequence and includes the structural genes for pesticin sensitivity and HMWP2. Mol Microbiol 1994; 13: 697-708. (Pubitemid 24266205)
17. Feodorova VA, Motin VL. Plague vaccines. In: Feodorova VA, Motin VL (eds.)Vaccines against bacterial biothreat pathogens. Kerala: Research Signpost, 2011: 176-233.
18. Andrews GP, Heath DG, Anderson GW Jr, Welkos SL, Friedlander AM. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun 1996; 64: 2180-2187. (Pubitemid 26167232)
19. Motin VL, Nakajima R, Smirvov GB, Brubaker RR. Passive immunity to yersiniae mediated by anti-recombinant V antigen and Protein A-V antigen fusion peptide. Infect Immun 1994; 62: 4192-4201. (Pubitemid 24301942)
20. Nakajima R, Motin VL, Brubaker RR. Suppression of cytokines in mice by Protein A-V antigen fusion peptide and restoration of synthesis by active immunization. Infect Immun 1995; 63: 3021-3029.
21. Motin VL, Nedialkov YA, Brubaker RR. V antigen-polyhistidine fusion peptide: binding to LcrH and active immunity against plague. Infect Immun 1996; 64: 4313-4318. (Pubitemid 26318158)
22. Williamson ED, Eley SM, Griffin KF et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 1995; 12: 223-230.
23. Quenee LE, Schneewind O. Plague vaccines and the molecular basis of immunity against Yersinia pestis. Hum Vaccin 2009; 5: 817-823.
24. Smiley ST. Current challenges in the development of vaccines for pneumonic plague. Expert Rev Vaccines 2008; 7: 209-221. (Pubitemid 351357956)
25. Titball RW, Williamson ED. Vaccination against bubonic and pneumonic plague. Vaccine 2001; 19: 4175-4184. (Pubitemid 32703638)
26. Titball RW, Williamson ED. Yersinia pestis (plague) vaccines. Expert Opin Biol Ther 2004; 4: 965-973. (Pubitemid 38843233)
27. Williamson ED, Titball RW. Vaccines against dangerous pathogens. Br Med Bull 2002; 62: 163-173. (Pubitemid 34832478)
28. Williamson ED, Duchars MG, Kohberger R. Predictive models and correlates of protection for testing biodefence vaccines. Expert Rev Vaccines 2010; 9: 527-537.
29. Brubaker RR. Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen). Infect Immun 2003; 71: 3673-3681. (Pubitemid 36753686)
30. DeBord KL, Anderson DM, Marketon MM et al. Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV. Infect Immun 2006; 74: 4910-4914. (Pubitemid 44157279)
31. Nedialkov YA, Motin VL, Brubaker RR. Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: amplification of interleukin-10. Infect Immun 1997; 65: 1196-1203. (Pubitemid 27146602)
32. Anisimov AP, Dentovskaya SV, Panfertsev EA et al. Amino acid and structural variability of Yersinia pestis LcrV protein. Infect Genet Evol 2010; 10: 137-145.
33. Motin VL, Pokrovskaya MS, Telepnev MV et al. The difference in the lcrV sequences between Yersinia pestis and Yersinia pseudotuberculosis and its application for characterization of Y. pseudotuberculosis strains. Microb Pathog 1992; 12: 165-175.
34. Cornelius CA, Quenee LE, Overheim KA et al. Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infect Immun 2008; 76: 5588-5597.
35. Fellows P, Adamovicz J, Hartings J et al. Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V). Vaccine 2010; 28: 7748-7756.
36. Welkos S, Norris S, Adamovicz J. Modified caspase-3 assay indicates correlation of caspase-3 activity with immunity of nonhuman primates to Yersinia pestis infection. Clin Vaccine Immunol 2008; 15: 1134-1137. (Pubitemid 352018332)
37. Williamson ED, Packer PJ, Waters EL et al. Recombinant (F11V) vaccine protects cynomolgus macaques against pneumonic plague. Vaccine 2011; 29: 4771-4777.
38. Mizel SB, Graff AH, Sriranganathan N et al. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clin Vaccine Immunol 2009; 16: 21-28.
39. Qiu Y, Liu Y, Qi Z et al. Comparison of immunological responses of plague vaccines F11rV270 and EV76 in Chinese-origin rhesus macaque, Macaca mulatta. Scand J Immunol 2010; 72: 425-433.
40. Stacy S, Pasquali A, Sexton VL, Cantwell AM, Kraig E, Dube PH. An age-old paradigm challenged: old baboons generate vigorous humoral immune responses to LcrV, a plague antigen. J Immunol 2008; 181: 109-115.
41. Williamson ED, Flick-Smith HC, Lebutt C et al. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun 2005; 73: 3598-3608. (Pubitemid 40745904)
42. Bashaw J, Norris S, Weeks S, Trevino S, Adamovicz JJ, Welkos S. Development of in vitro correlate assays of immunity to infection with Yersinia pestis. Clin Vaccine Immunol 2007; 14: 605-616.
43. Lin JS, Park S, Adamovicz JJ et al. TNFalpha and IFNgamma contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague. Vaccine 2010; 29: 357-362.
44. Weeks S, Hill J, Friedlander A, Welkos S. Anti-V antigen antibody protects macrophages from Yersinia pestis-induced cell death and promotes phagocytosis. Microb Pathog 2002; 32: 227-237. (Pubitemid 34729217)
45. Wang S, Heilman D, Liu F et al. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine 2004; 22: 3348-3357. (Pubitemid 39078752)
46. Wang S, Joshi S, Mboudjeka I et al. Relative immunogenicity and protection potential of candidate Yersinia pestis antigens against lethal mucosal plague challenge in Balb/C mice. Vaccine 2008; 26: 1664-1674.
47. Wang Z, Zhou L, Qi Z et al. Long-term observation of subunit vaccine F1-rV270 against Yersinia pestis in mice. Clin Vaccine Immunol 2010; 17: 199-201.
48. Torres-Escobar A, Juarez-Rodriguez MD, Gunn BM, Branger CG, Tinge SA, Curtiss R, 3rd. Fine-tuning synthesis of Yersinia pestis LcrV from runaway-like replication balanced-lethal plasmid in a Salmonella enterica serovar typhimurium vaccine induces protection against a lethal Y. pestis challenge in mice. Infect Immun 2010; 78: 2529-2543.
49. Sun W, Roland KL, Curtiss R, 3rd. Developing live vaccines against Yersinia pestis. J Infect Dev Ctries 2011; 5: 614-627.
50. Daniel C, Sebbane F, Poiret S et al. Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV. Vaccine 2009; 27: 1141-1144.
51. Chiuchiolo MJ, Boyer JL, Krause A, Senina S, Hackett NR, Crystal RG. Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen. J Infect Dis 2006; 194: 1249-1257. (Pubitemid 44630970)
52. Croyle MA, Patel A, Tran KN et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE 2008; 3: e3548.
53. 1 cells are required at the time of challenge for optimal protection. Vaccine 2008; 26: 6329-6337.
54. Rocke TE, Iams KP, Dawe S et al. Further development of raccoon poxvirus-vectored vaccines against plague (Yersinia pestis). Vaccine 2009; 28: 338-344.
55. Brewoo JN, Powell TD, Stinchcomb DT, Osorio JE. Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice. Vaccine 2010; 28: 5891-5899.
56. Saltykova RA, Faibich MM. [Experience from a 30-year study of the stability of the properties of the plague vaccine strain EV in the USSR.] Zh Mikrobiol Epidemiol Immunobiol 1975; 6: 3-8. Russian.
57. Feodorova VA, Pan'kina LN, Savostina EP et al. A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs. Vaccine 2007; 25: 7620-7628. (Pubitemid 47538817)
58. Feodorova VA, Pan'kina LN, Savostina EP et al. Pleiotropic effects of the lpxM mutation in Yersinia pestis resulting in modification of the biosynthesis of major immunoreactive antigens. Vaccine 2009; 27: 2240-2250.
59. Montminy SW, Khan N, McGrath S et al. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat Immunol 2006; 7: 1066-1073. (Pubitemid 44420651)
60. Sha J, Agar SL, Baze WB et al. Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague. Infect Immun 2008; 76: 1390-1409. (Pubitemid 351561984)
61. Tidhar A, Flashner Y, Cohen S et al. The NlpD lipoprotein is a novel Yersinia pestis virulence factor essential for the development of plague. PLoS ONE 2009; 4: e7023.
62. Alvarez ML, Cardineau GA. Prevention of bubonic and pneumonic plague using plant-derived vaccines. Biotechnol Adv 2010; 28: 184-196.
63. Lin JS, Kummer LW, Szaba FM, Smiley ST. IL-17 contributes to cell-mediated defense against pulmonary yersinia pestis infection. J Immunol 2011; 186: 1675-1684.
64. Smiley ST. Cell-mediated defense against Yersinia pestis infection. Adv Exp Med Biol 2007; 603: 376-386.
65. Smiley ST. Immune defense against pneumonic plague. Immunol Rev 2008; 225: 256-271.
66. Li B, Zhou L, Guo J et al. High-throughput identification of new protective antigens from aYersinia pestis live vaccine by enzyme-linked immunospot assay. Infect Immun 2009; 77: 4356-4561.
67. 1 T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge. Vaccine 2011; 29: 6802-6809.
68. Nakajima R, Brubaker RR. Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. Infect Immun 1993; 61: 23-31. (Pubitemid 23015395)
69. Knirel YA, Dentovskaya SV, Senchenkova SN, Shaikhutdinova RZ, Kocharova NA, Anisimov AP. Structural features and structural variability of the lipopolysaccharide of Yersinia pestis, the cause of plague. J Endotoxin Res 2006; 12: 3-9. (Pubitemid 43169509)
70. Telepnev MV, Klimpel GR, Haithcoat J, Knirel YA, Anisimov AP, Motin VL. Tetraacylated lipopolysaccharide of Yersinia pestis can inhibit multiple Toll-like receptor-mediated signaling pathways in human dendritic cells. J Infect Dis 2009; 200: 1694-1702.
71. Price PA, Jin J, Goldman WE. Pulmonary infection by Yersinia pestis rapidly establishes a permissive environment for microbial proliferation. Proc Natl Acad Sci USA 2012; 109: 3083-3088.
72. Lu S. Two is better than one. Lancet Infect Dis 2011; 11: 889-891.